Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beijing Tongrentang CoSHSE:600085 -0.41%81 Net Margin % is 10.10% as of Mar. 2026, which is 26% above its 10-year median of 8.01. GuruFocus rates SHSE:600085 with a GF Score™ of 81/100 and a GF Value™ of ¥35.95 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 959 Drug Manufacturers companies, Beijing Tongrentang Co ranks better than 53.7% on this metric.
Beijing Tongrentang Co (SHSE:600085) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Beijing Tongrentang Co Net Margin % Related Terms
Beijing Tongrentang Co Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Beijing Tongrentang Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beijing Tongrentang Co Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Beijing Tongrentang Co's Net Margin % distribution charts can be found below:
* The bar in red indicates where Beijing Tongrentang Co's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Tongrentang Co (SHSE:600085) has a Net Margin % of 10.10% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Beijing Tongrentang Co and its competitors. This is 26% above median its historical median of 8.01. Over the past decade, Beijing Tongrentang Co's Net Margin % has ranged from 6.48 to 9.34. According to the industry distribution chart, Beijing Tongrentang Co ranks #444 out of 959 companies in the Drug Manufacturers industry, placing it in the top 46.3%.
Is Beijing Tongrentang Co's Net Margin % too high?
Beijing Tongrentang Co's current Net Margin % of 10.10% is 26% above median its 10-year median of 8.01. Over the past 10 years, this metric has ranged from a low of 6.48 to a high of 9.34. The Drug Manufacturers industry median Net Margin % is 5.53. Beijing Tongrentang Co's value of 10.10% is 82.6% above this industry median. Based on the distribution chart, Beijing Tongrentang Co ranks #444 out of 959 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Beijing Tongrentang Co has a GF Score™ of 81/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Beijing Tongrentang Co's Net Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Beijing Tongrentang Co ranks #444 out of 959 companies for Net Margin %. This puts Beijing Tongrentang Co in the upper half of its industry. The industry median Net Margin % is 5.53. Beijing Tongrentang Co's value of 10.10% is 82.6% above this benchmark. Historically, Beijing Tongrentang Co's own Net Margin % has ranged from 6.48 to 9.34 over the past decade. While the company's 10-year median is 8.01 vs. the industry median of 5.53, Beijing Tongrentang Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.53, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beijing Tongrentang Co's current Net Margin % of 10.10% is 82.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Beijing Tongrentang Co and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beijing Tongrentang Co's current Net Margin % is 10.10%, which is 26% above median its own 10-year median of 8.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Tongrentang Co stock overvalued right now?
Based on GuruFocus' analysis, Beijing Tongrentang Co (SHSE:600085) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥35.95, compared to a current price of ¥24.35 — trading 32.3% below its estimated fair value. The current Net Margin % is 10.10%, which is 26% above median its 10-year median of 8.01 and 82.6% above the Drug Manufacturers industry median of 5.53. Beijing Tongrentang Co's overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Beijing Tongrentang Co (SHSE:600085), the current Net Margin % is 10.10% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beijing Tongrentang Co (SHSE:600085) Overvalued in 2026?
Based on GuruFocus' analysis, Beijing Tongrentang Co stock appears to be undervalued.
The current stock price of ¥24.35 is trading 32.3% below its estimated GF Value™ of ¥35.95.
GuruFocus considers Beijing Tongrentang Co to be Significantly Undervalued.
Key valuation signals for SHSE:600085:
Net Margin %: 10.10% (26% above median its 10-year median of 8.01)
GF Value™: ¥35.95 vs. price of ¥24.35 (32.3% below fair value)
Industry Position: 82.6% above the Drug Manufacturers median (#444 of 959)
No single metric tells the full story. See the SHSE:600085 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beijing Tongrentang Co Ltd is a China-based company operating in the traditional Chinese medicinal industry. The company produces modern pharmaceuticals and operates retail businesses and medical services. The company's main products consist of Liuwei Dihuang series, Tongren Dahuoluo series, Tongren Niuhuang Qingxin series, Angong Niuhuang series, and Donkey-hide gelatin series. It distributes its products under the brand of Tongrentang.
81GF Score
Get the complete analysis for SHSE:600085
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600085 has been successfully added to your 
